Keratoacanthoma - Keratoakantoma
☆ Germaniyaning 2022 yilgi Stiftung Warentest natijalariga ko'ra, iste'molchilarning ModelDermdan qoniqish darajasi pullik teletibbiyot maslahatlariga qaraganda bir oz pastroq bo'lgan.
Oddiy Keratoakantoma (Keratoacanthoma)
References
Keratoacanthoma (KA) tez o'sishi va o'z-o'zidan regressga tushishi bilan mashhur teri shishi. Bu odatda quyosh nuri ta'siriga duchor bo'lgan keksa, ochiq teriga ega erkaklarda uchraydi. Eksizyon yoki Mohs mikrografik jarrohlik yordamida jarrohlik yo'li bilan olib tashlash odatiy davolanish bo'lsa-da, boshqa turli xil davolash usullari mavjud.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) - past darajadagi o'sma bo'lib, u teridagi ma'lum bezlarda boshlanadi va mikroskop ostida squamous cell carcinoma (SCC) ga o'xshaydi. KA ni invaziv SCC shakli sifatida tasniflash kerakligi haqida munozaralar davom etmoqda.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) odamlarda, ayniqsa keksa odamlarda saratonning ikkinchi eng keng tarqalgan turi. Jarrohlik odatda cSCCni davolash uchun ishlatiladi, ammo jarrohlik qilolmaydigan yoki qilmaslikni tanlagan ba'zi bemorlar uchun intralezyonal davolash kabi boshqa variantlar ko'rib chiqilishi mumkin. An'anaviy intralezyonal davolash usullari (methotrexate or 5-fluorouracil) qo'llanilgan, ammo intralezyonal immunoterapiya va onkolitik viroterapiya kabi yangi yondashuvlar bo'yicha tadqiqotlar davom etmoqda. Bu erda biz cSCC uchun klassik usullardan eng zamonaviy strategiyalargacha bo'lgan turli xil intralezyonal davolash usullarini ko'rib chiqamiz.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Mikroskop ostida keratoakantoma (keratoacanthoma) skuamoz hujayrali karsinomaga juda o'xshaydi. Ba'zi patologlar keratoakantoma (keratoacanthoma) ni xavfli o'simta emas, balki alohida ob'ekt sifatida tasniflashsa-da, klinik va gistologik keratoakantoma (keratoacanthoma) ning taxminan 6% invaziv va agressiv skuamoz hujayrali saratonga o'tadi.
○ Diagnoz va davolash
#Dermoscopy
#Skin biopsy